NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $132,816 | -54.7% | 124,128 | +9.7% | 0.00% | -100.0% |
| Q2 2023 | $293,174 | +61.0% | 113,195 | +153.6% | 0.00% | – |
| Q1 2023 | $182,145 | -20.6% | 44,644 | -2.3% | 0.00% | – |
| Q4 2022 | $229,343 | -27.7% | 45,686 | +87.8% | 0.00% | -100.0% |
| Q3 2022 | $317,000 | +98.1% | 24,332 | +94.7% | 0.00% | – |
| Q2 2022 | $160,000 | -35.0% | 12,500 | -22.8% | 0.00% | – |
| Q1 2022 | $246,000 | -32.4% | 16,183 | -21.5% | 0.00% | -100.0% |
| Q4 2021 | $364,000 | -36.6% | 20,625 | -24.7% | 0.00% | 0.0% |
| Q3 2021 | $574,000 | +46.1% | 27,380 | +36.5% | 0.00% | 0.0% |
| Q2 2021 | $393,000 | -37.9% | 20,060 | -8.1% | 0.00% | 0.0% |
| Q1 2021 | $633,000 | -38.4% | 21,822 | -35.7% | 0.00% | -50.0% |
| Q4 2020 | $1,028,000 | +81.6% | 33,962 | -4.7% | 0.00% | +100.0% |
| Q3 2020 | $566,000 | -29.9% | 35,651 | -13.1% | 0.00% | -50.0% |
| Q2 2020 | $807,000 | +103.8% | 41,024 | +27.7% | 0.00% | +100.0% |
| Q1 2020 | $396,000 | – | 32,122 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |